

# **2021-2027 Global and Regional Spinal Muscular Atrophy Medicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report Standard Version**

<https://marketpublishers.com/r/224406461AB8EN.html>

Date: March 2021

Pages: 140

Price: US\$ 3,500.00 (Single User License)

ID: 224406461AB8EN

## **Abstracts**

The research team projects that the Spinal Muscular Atrophy Medicine market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries. Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Astellas Pharma Inc.

AveXis, Inc.

Bioblast Pharma Ltd.

Cytokinetics, Inc. 24

F. Hoffmann-La Roche Ltd.

Genethon

Genzyme Corporation

GMP-Orphan SAS  
Ionis Pharmaceuticals, Inc.  
Longevity Biotech, Inc  
Neurodyn Inc.  
Neurotune AG  
Novartis AG  
Sarepta Therapeutics, Inc.  
Voyager Therapeutics, Inc.  
Vybion, Inc.  
WAVE Life Sciences Ltd.

By Type

LMI-070  
ND-602  
NT-1654  
Nusinersen  
NXD-30001  
Others

By Application

Hospital  
Clinic  
Others

By Regions/Countries:

North America  
United States  
Canada  
Mexico

East Asia

China  
Japan  
South Korea

Europe

Germany  
United Kingdom  
France

Italy  
Russia  
Spain  
Netherlands  
Switzerland  
Poland

South Asia  
India  
Pakistan  
Bangladesh

Southeast Asia  
Indonesia  
Thailand  
Singapore  
Malaysia  
Philippines  
Vietnam  
Myanmar

Middle East  
Turkey  
Saudi Arabia  
Iran  
United Arab Emirates  
Israel  
Iraq  
Qatar  
Kuwait  
Oman

Africa  
Nigeria  
South Africa  
Egypt  
Algeria  
Morocco

Oceania

Australia

New Zealand

South America

Brazil

Argentina

Colombia

Chile

Venezuela

Peru

Puerto Rico

Ecuador

Rest of the World

Kazakhstan

#### Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

#### Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its

impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Spinal Muscular Atrophy Medicine 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with base year as 2020.

#### Key Indicators Analysed

**Market Players & Competitor Analysis:** The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

**Global and Regional Market Analysis:** The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its production, consumption, import & export, sales volume & revenue forecast.

**Market Analysis by Product Type:** The report covers majority Product Types in the Spinal Muscular Atrophy Medicine Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

**Market Analysis by Application Type:** Based on the Spinal Muscular Atrophy Medicine Industry and its applications, the market is further sub-segmented into several major Application of its industry. It provides you with the market size, CAGR & forecast by each industry applications.

**Market Trends:** Market key trends which include Increased Competition and Continuous Innovations.

**Opportunities and Drivers:** Identifying the Growing Demands and New Technology

**Porters Five Force Analysis:** The report will provide with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

#### COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Spinal Muscular Atrophy Medicine market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

## Contents

### CHAPTER 1 INDUSTRY OVERVIEW

- 1.1 Definition
- 1.2 Assumptions
- 1.3 Research Scope
- 1.4 Market Analysis by Regions
  - 1.4.1 North America Market States and Outlook (2022-2027)
  - 1.4.2 East Asia Market States and Outlook (2022-2027)
  - 1.4.3 Europe Market States and Outlook (2022-2027)
  - 1.4.4 South Asia Market States and Outlook (2022-2027)
  - 1.4.5 Southeast Asia Market States and Outlook (2022-2027)
  - 1.4.6 Middle East Market States and Outlook (2022-2027)
  - 1.4.7 Africa Market States and Outlook (2022-2027)
  - 1.4.8 Oceania Market States and Outlook (2022-2027)
  - 1.4.9 South America Market States and Outlook (2022-2027)
- 1.5 Global Spinal Muscular Atrophy Medicine Market Size Analysis from 2022 to 2027
  - 1.5.1 Global Spinal Muscular Atrophy Medicine Market Size Analysis from 2022 to 2027 by Consumption Volume
  - 1.5.2 Global Spinal Muscular Atrophy Medicine Market Size Analysis from 2022 to 2027 by Value
  - 1.5.3 Global Spinal Muscular Atrophy Medicine Price Trends Analysis from 2022 to 2027
- 1.6 COVID-19 Outbreak: Spinal Muscular Atrophy Medicine Industry Impact

### CHAPTER 2 GLOBAL SPINAL MUSCULAR ATROPHY MEDICINE COMPETITION BY TYPES, APPLICATIONS, AND TOP REGIONS AND COUNTRIES

- 2.1 Global Spinal Muscular Atrophy Medicine (Volume and Value) by Type
  - 2.1.1 Global Spinal Muscular Atrophy Medicine Consumption and Market Share by Type (2016-2021)
  - 2.1.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2016-2021)
- 2.2 Global Spinal Muscular Atrophy Medicine (Volume and Value) by Application
  - 2.2.1 Global Spinal Muscular Atrophy Medicine Consumption and Market Share by Application (2016-2021)
  - 2.2.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2016-2021)

## 2.3 Global Spinal Muscular Atrophy Medicine (Volume and Value) by Regions

2.3.1 Global Spinal Muscular Atrophy Medicine Consumption and Market Share by Regions (2016-2021)

2.3.2 Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Regions (2016-2021)

## **CHAPTER 3 PRODUCTION MARKET ANALYSIS**

### 3.1 Global Production Market Analysis

3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

3.1.2 2016-2021 Major Manufacturers Performance and Market Share

### 3.2 Regional Production Market Analysis

3.2.1 2016-2021 Regional Market Performance and Market Share

3.2.2 North America Market

3.2.3 East Asia Market

3.2.4 Europe Market

3.2.5 South Asia Market

3.2.6 Southeast Asia Market

3.2.7 Middle East Market

3.2.8 Africa Market

3.2.9 Oceania Market

3.2.10 South America Market

3.2.11 Rest of the World Market

## **CHAPTER 4 GLOBAL SPINAL MUSCULAR ATROPHY MEDICINE SALES, CONSUMPTION, EXPORT, IMPORT BY REGIONS (2016-2021)**

4.1 Global Spinal Muscular Atrophy Medicine Consumption by Regions (2016-2021)

4.2 North America Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.3 East Asia Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.4 Europe Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.5 South Asia Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.6 Southeast Asia Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)



4.7 Middle East Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.8 Africa Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.9 Oceania Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

4.10 South America Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

## **CHAPTER 5 NORTH AMERICA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

5.1 North America Spinal Muscular Atrophy Medicine Consumption and Value Analysis

5.1.1 North America Spinal Muscular Atrophy Medicine Market Under COVID-19

5.2 North America Spinal Muscular Atrophy Medicine Consumption Volume by Types

5.3 North America Spinal Muscular Atrophy Medicine Consumption Structure by Application

5.4 North America Spinal Muscular Atrophy Medicine Consumption by Top Countries

5.4.1 United States Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

5.4.2 Canada Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

5.4.3 Mexico Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 6 EAST ASIA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

6.1 East Asia Spinal Muscular Atrophy Medicine Consumption and Value Analysis

6.1.1 East Asia Spinal Muscular Atrophy Medicine Market Under COVID-19

6.2 East Asia Spinal Muscular Atrophy Medicine Consumption Volume by Types

6.3 East Asia Spinal Muscular Atrophy Medicine Consumption Structure by Application

6.4 East Asia Spinal Muscular Atrophy Medicine Consumption by Top Countries

6.4.1 China Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

6.4.2 Japan Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

6.4.3 South Korea Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 7 EUROPE SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

### 7.1 Europe Spinal Muscular Atrophy Medicine Consumption and Value Analysis

#### 7.1.1 Europe Spinal Muscular Atrophy Medicine Market Under COVID-19

### 7.2 Europe Spinal Muscular Atrophy Medicine Consumption Volume by Types

### 7.3 Europe Spinal Muscular Atrophy Medicine Consumption Structure by Application

### 7.4 Europe Spinal Muscular Atrophy Medicine Consumption by Top Countries

#### 7.4.1 Germany Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.2 UK Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.3 France Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.4 Italy Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.5 Russia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.6 Spain Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.7 Netherlands Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.8 Switzerland Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 7.4.9 Poland Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 8 SOUTH ASIA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

### 8.1 South Asia Spinal Muscular Atrophy Medicine Consumption and Value Analysis

#### 8.1.1 South Asia Spinal Muscular Atrophy Medicine Market Under COVID-19

### 8.2 South Asia Spinal Muscular Atrophy Medicine Consumption Volume by Types

### 8.3 South Asia Spinal Muscular Atrophy Medicine Consumption Structure by Application

### 8.4 South Asia Spinal Muscular Atrophy Medicine Consumption by Top Countries

#### 8.4.1 India Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 8.4.2 Pakistan Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 8.4.3 Bangladesh Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 9 SOUTHEAST ASIA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

### 9.1 Southeast Asia Spinal Muscular Atrophy Medicine Consumption and Value Analysis

#### 9.1.1 Southeast Asia Spinal Muscular Atrophy Medicine Market Under COVID-19

### 9.2 Southeast Asia Spinal Muscular Atrophy Medicine Consumption Volume by Types

### 9.3 Southeast Asia Spinal Muscular Atrophy Medicine Consumption Structure by Application

### 9.4 Southeast Asia Spinal Muscular Atrophy Medicine Consumption by Top Countries

#### 9.4.1 Indonesia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 9.4.2 Thailand Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 9.4.3 Singapore Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 9.4.4 Malaysia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 9.4.5 Philippines Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 9.4.6 Vietnam Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 9.4.7 Myanmar Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 10 MIDDLE EAST SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

### 10.1 Middle East Spinal Muscular Atrophy Medicine Consumption and Value Analysis

#### 10.1.1 Middle East Spinal Muscular Atrophy Medicine Market Under COVID-19

### 10.2 Middle East Spinal Muscular Atrophy Medicine Consumption Volume by Types

### 10.3 Middle East Spinal Muscular Atrophy Medicine Consumption Structure by Application

### 10.4 Middle East Spinal Muscular Atrophy Medicine Consumption by Top Countries

#### 10.4.1 Turkey Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 10.4.2 Saudi Arabia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

#### 10.4.3 Iran Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

10.4.4 United Arab Emirates Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

10.4.5 Israel Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

10.4.6 Iraq Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

10.4.7 Qatar Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

10.4.8 Kuwait Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

10.4.9 Oman Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 11 AFRICA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

11.1 Africa Spinal Muscular Atrophy Medicine Consumption and Value Analysis

11.1.1 Africa Spinal Muscular Atrophy Medicine Market Under COVID-19

11.2 Africa Spinal Muscular Atrophy Medicine Consumption Volume by Types

11.3 Africa Spinal Muscular Atrophy Medicine Consumption Structure by Application

11.4 Africa Spinal Muscular Atrophy Medicine Consumption by Top Countries

11.4.1 Nigeria Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

11.4.2 South Africa Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

11.4.3 Egypt Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

11.4.4 Algeria Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

11.4.5 Morocco Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 12 OCEANIA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

12.1 Oceania Spinal Muscular Atrophy Medicine Consumption and Value Analysis

12.2 Oceania Spinal Muscular Atrophy Medicine Consumption Volume by Types

12.3 Oceania Spinal Muscular Atrophy Medicine Consumption Structure by Application

12.4 Oceania Spinal Muscular Atrophy Medicine Consumption by Top Countries

12.4.1 Australia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

2021

12.4.2 New Zealand Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 13 SOUTH AMERICA SPINAL MUSCULAR ATROPHY MEDICINE MARKET ANALYSIS**

13.1 South America Spinal Muscular Atrophy Medicine Consumption and Value Analysis

13.1.1 South America Spinal Muscular Atrophy Medicine Market Under COVID-19

13.2 South America Spinal Muscular Atrophy Medicine Consumption Volume by Types

13.3 South America Spinal Muscular Atrophy Medicine Consumption Structure by Application

13.4 South America Spinal Muscular Atrophy Medicine Consumption Volume by Major Countries

13.4.1 Brazil Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.2 Argentina Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.3 Columbia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.4 Chile Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.5 Venezuela Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.6 Peru Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.7 Puerto Rico Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

13.4.8 Ecuador Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

## **CHAPTER 14 COMPANY PROFILES AND KEY FIGURES IN SPINAL MUSCULAR ATROPHY MEDICINE BUSINESS**

14.1 Astellas Pharma Inc.

14.1.1 Astellas Pharma Inc. Company Profile

14.1.2 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Specification

14.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Production Capacity,

## Revenue, Price and Gross Margin (2016-2021)

### 14.2 AveXis, Inc.

#### 14.2.1 AveXis, Inc. Company Profile

#### 14.2.2 AveXis, Inc. Spinal Muscular Atrophy Medicine Product Specification

#### 14.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.3 Bioblast Pharma Ltd.

#### 14.3.1 Bioblast Pharma Ltd. Company Profile

#### 14.3.2 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Specification

#### 14.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.4 Cytokinetics, Inc.

#### 14.4.1 Cytokinetics, Inc. 24 Company Profile

#### 14.4.2 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Specification

#### 14.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.5 F. Hoffmann-La Roche Ltd.

#### 14.5.1 F. Hoffmann-La Roche Ltd. Company Profile

#### 14.5.2 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Specification

#### 14.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.6 Genethon

#### 14.6.1 Genethon Company Profile

#### 14.6.2 Genethon Spinal Muscular Atrophy Medicine Product Specification

#### 14.6.3 Genethon Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.7 Genzyme Corporation

#### 14.7.1 Genzyme Corporation Company Profile

#### 14.7.2 Genzyme Corporation Spinal Muscular Atrophy Medicine Product Specification

#### 14.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.8 GMP-Orphan SAS

#### 14.8.1 GMP-Orphan SAS Company Profile

#### 14.8.2 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Specification

#### 14.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 14.9 Ionis Pharmaceuticals, Inc.

#### 14.9.1 Ionis Pharmaceuticals, Inc. Company Profile

14.9.2 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Specification

14.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.10 Longevity Biotech, Inc

14.10.1 Longevity Biotech, Inc Company Profile

14.10.2 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Specification

14.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.11 Neurodyn Inc.

14.11.1 Neurodyn Inc. Company Profile

14.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Specification

14.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.12 Neurotune AG

14.12.1 Neurotune AG Company Profile

14.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Product Specification

14.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.13 Novartis AG

14.13.1 Novartis AG Company Profile

14.13.2 Novartis AG Spinal Muscular Atrophy Medicine Product Specification

14.13.3 Novartis AG Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.14 Sarepta Therapeutics, Inc.

14.14.1 Sarepta Therapeutics, Inc. Company Profile

14.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Specification

14.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.15 Voyager Therapeutics, Inc.

14.15.1 Voyager Therapeutics, Inc. Company Profile

14.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Specification

14.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

14.16 Vybion, Inc.

14.16.1 Vybion, Inc. Company Profile

- 14.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Product Specification
- 14.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)
- 14.17 WAVE Life Sciences Ltd.
  - 14.17.1 WAVE Life Sciences Ltd. Company Profile
  - 14.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Specification
  - 14.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

## **CHAPTER 15 GLOBAL SPINAL MUSCULAR ATROPHY MEDICINE MARKET FORECAST (2022-2027)**

- 15.1 Global Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Price Forecast (2022-2027)
  - 15.1.1 Global Spinal Muscular Atrophy Medicine Consumption Volume and Growth Rate Forecast (2022-2027)
  - 15.1.2 Global Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)
- 15.2 Global Spinal Muscular Atrophy Medicine Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
  - 15.2.1 Global Spinal Muscular Atrophy Medicine Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
  - 15.2.2 Global Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast by Regions (2022-2027)
  - 15.2.3 North America Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
  - 15.2.4 East Asia Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
  - 15.2.5 Europe Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
  - 15.2.6 South Asia Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
  - 15.2.7 Southeast Asia Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
  - 15.2.8 Middle East Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
  - 15.2.9 Africa Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)



15.2.10 Oceania Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.2.11 South America Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)

15.3 Global Spinal Muscular Atrophy Medicine Consumption Volume, Revenue and Price Forecast by Type (2022-2027)

15.3.1 Global Spinal Muscular Atrophy Medicine Consumption Forecast by Type (2022-2027)

15.3.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Type (2022-2027)

15.3.3 Global Spinal Muscular Atrophy Medicine Price Forecast by Type (2022-2027)

15.4 Global Spinal Muscular Atrophy Medicine Consumption Volume Forecast by Application (2022-2027)

15.5 Spinal Muscular Atrophy Medicine Market Forecast Under COVID-19

## **CHAPTER 16 CONCLUSIONS**

Research Methodology

### **List of Tables and Figures**

Figure Product Picture

Figure North America Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure United States Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Canada Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Mexico Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure East Asia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure China Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Japan Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure South Korea Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Europe Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Germany Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure UK Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure France Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Italy Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Russia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Spain Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Netherlands Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Switzerland Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Poland Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure South Asia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure India Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Pakistan Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Bangladesh Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Southeast Asia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Indonesia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Thailand Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Singapore Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Malaysia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Philippines Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Vietnam Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure Myanmar Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Middle East Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Turkey Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Saudi Arabia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Iran Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure United Arab Emirates Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Israel Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Iraq Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Qatar Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Kuwait Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Oman Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Africa Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Nigeria Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure South Africa Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Egypt Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Algeria Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Algeria Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Oceania Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Australia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure New Zealand Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate

(2022-2027)

Figure South America Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Brazil Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Argentina Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Columbia Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Chile Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Venezuela Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Peru Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Puerto Rico Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Ecuador Spinal Muscular Atrophy Medicine Revenue (\$) and Growth Rate (2022-2027)

Figure Global Spinal Muscular Atrophy Medicine Market Size Analysis from 2022 to 2027 by Consumption Volume

Figure Global Spinal Muscular Atrophy Medicine Market Size Analysis from 2022 to 2027 by Value

Table Global Spinal Muscular Atrophy Medicine Price Trends Analysis from 2022 to 2027

Table Global Spinal Muscular Atrophy Medicine Consumption and Market Share by Type (2016-2021)

Table Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Type (2016-2021)

Table Global Spinal Muscular Atrophy Medicine Consumption and Market Share by Application (2016-2021)

Table Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Application (2016-2021)

Table Global Spinal Muscular Atrophy Medicine Consumption and Market Share by Regions (2016-2021)

Table Global Spinal Muscular Atrophy Medicine Revenue and Market Share by Regions (2016-2021)

Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin

Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Major Manufacturers Capacity and Total Capacity  
Table 2016-2021 Major Manufacturers Capacity Market Share  
Table 2016-2021 Major Manufacturers Production and Total Production  
Table 2016-2021 Major Manufacturers Production Market Share  
Table 2016-2021 Major Manufacturers Revenue and Total Revenue  
Table 2016-2021 Major Manufacturers Revenue Market Share  
Table 2016-2021 Regional Market Capacity and Market Share  
Table 2016-2021 Regional Market Production and Market Share  
Table 2016-2021 Regional Market Revenue and Market Share  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate  
Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin  
Figure 2016-2021 Capacity, Production and Growth Rate  
Figure 2016-2021 Revenue, Gross Margin and Growth Rate

Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin

Figure 2016-2021 Capacity, Production and Growth Rate

Figure 2016-2021 Revenue, Gross Margin and Growth Rate

Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin

Figure 2016-2021 Capacity, Production and Growth Rate

Figure 2016-2021 Revenue, Gross Margin and Growth Rate

Table 2016-2021 Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin

Figure 2016-2021 Capacity, Production and Growth Rate

Figure 2016-2021 Revenue, Gross Margin and Growth Rate

Table Global Spinal Muscular Atrophy Medicine Consumption by Regions (2016-2021)

Figure Global Spinal Muscular Atrophy Medicine Consumption Share by Regions (2016-2021)

Table North America Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table East Asia Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table Europe Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table South Asia Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table Southeast Asia Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table Middle East Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table Africa Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table Oceania Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Table South America Spinal Muscular Atrophy Medicine Sales, Consumption, Export, Import (2016-2021)

Figure North America Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure North America Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table North America Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table North America Spinal Muscular Atrophy Medicine Consumption Volume by Types  
Table North America Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table North America Spinal Muscular Atrophy Medicine Consumption by Top Countries  
Figure United States Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Canada Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Mexico Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure East Asia Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure East Asia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table East Asia Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table East Asia Spinal Muscular Atrophy Medicine Consumption Volume by Types  
Table East Asia Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table East Asia Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure China Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Japan Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure South Korea Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Europe Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure Europe Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table Europe Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table Europe Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table Europe Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table Europe Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure Germany Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure UK Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure France Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Italy Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Russia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Spain Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Netherlands Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Switzerland Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Poland Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure South Asia Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure South Asia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table South Asia Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table South Asia Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table South Asia Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table South Asia Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure India Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Pakistan Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Bangladesh Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Southeast Asia Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure Southeast Asia Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table Southeast Asia Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table Southeast Asia Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table Southeast Asia Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table Southeast Asia Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure Indonesia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Thailand Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021



Figure Singapore Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Malaysia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Philippines Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Vietnam Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Myanmar Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Middle East Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure Middle East Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table Middle East Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table Middle East Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table Middle East Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table Middle East Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure Turkey Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Saudi Arabia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Iran Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure United Arab Emirates Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Israel Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Iraq Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Qatar Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Kuwait Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Oman Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Africa Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure Africa Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table Africa Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table Africa Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table Africa Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table Africa Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure Nigeria Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure South Africa Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Egypt Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Algeria Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Algeria Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Oceania Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure Oceania Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table Oceania Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table Oceania Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table Oceania Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table Oceania Spinal Muscular Atrophy Medicine Consumption by Top Countries

Figure Australia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure New Zealand Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure South America Spinal Muscular Atrophy Medicine Consumption and Growth Rate (2016-2021)

Figure South America Spinal Muscular Atrophy Medicine Revenue and Growth Rate (2016-2021)

Table South America Spinal Muscular Atrophy Medicine Sales Price Analysis (2016-2021)

Table South America Spinal Muscular Atrophy Medicine Consumption Volume by Types

Table South America Spinal Muscular Atrophy Medicine Consumption Structure by Application

Table South America Spinal Muscular Atrophy Medicine Consumption Volume by Major Countries

Figure Brazil Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Argentina Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

2021

Figure Columbia Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Chile Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Venezuela Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Peru Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Puerto Rico Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Figure Ecuador Spinal Muscular Atrophy Medicine Consumption Volume from 2016 to 2021

Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Product Specification

Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

AveXis, Inc. Spinal Muscular Atrophy Medicine Product Specification

AveXis, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Product Specification

Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Product Specification

Table Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Product Specification

F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Genethon Spinal Muscular Atrophy Medicine Product Specification

Genethon Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Genzyme Corporation Spinal Muscular Atrophy Medicine Product Specification

Genzyme Corporation Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

GMP-Orphan SAS Spinal Muscular Atrophy Medicine Product Specification

GMP-Orphan SAS Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Product Specification

Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Product Specification  
Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Production Capacity,  
Revenue, Price and Gross Margin (2016-2021)

Neurodyn Inc. Spinal Muscular Atrophy Medicine Product Specification  
Neurodyn Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price  
and Gross Margin (2016-2021)

Neurotune AG Spinal Muscular Atrophy Medicine Product Specification  
Neurotune AG Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price  
and Gross Margin (2016-2021)

Novartis AG Spinal Muscular Atrophy Medicine Product Specification  
Novartis AG Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price  
and Gross Margin (2016-2021)

Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Specification  
Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Capacity,  
Revenue, Price and Gross Margin (2016-2021)

Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Product Specification  
Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Production Capacity,  
Revenue, Price and Gross Margin (2016-2021)

Vybion, Inc. Spinal Muscular Atrophy Medicine Product Specification  
Vybion, Inc. Spinal Muscular Atrophy Medicine Production Capacity, Revenue, Price  
and Gross Margin (2016-2021)

WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Product Specification  
WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Production Capacity,  
Revenue, Price and Gross Margin (2016-2021)

Figure Global Spinal Muscular Atrophy Medicine Consumption Volume and Growth  
Rate Forecast (2022-2027)

Figure Global Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Table Global Spinal Muscular Atrophy Medicine Consumption Volume Forecast by  
Regions (2022-2027)

Table Global Spinal Muscular Atrophy Medicine Value Forecast by Regions  
(2022-2027)

Figure North America Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure North America Spinal Muscular Atrophy Medicine Value and Growth Rate  
Forecast (2022-2027)

Figure United States Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure United States Spinal Muscular Atrophy Medicine Value and Growth Rate

Forecast (2022-2027)

Figure Canada Spinal Muscular Atrophy Medicine Consumption and Growth Rate

Forecast (2022-2027)

Figure Canada Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure Mexico Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure Mexico Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure East Asia Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure East Asia Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure China Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure China Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure Japan Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure Japan Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure South Korea Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure South Korea Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure Europe Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure Europe Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure Germany Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure Germany Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure UK Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast  
(2022-2027)

Figure UK Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast  
(2022-2027)

Figure France Spinal Muscular Atrophy Medicine Consumption and Growth Rate  
Forecast (2022-2027)

Figure France Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Italy Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Italy Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Russia Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Russia Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Spain Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Spain Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Netherlands Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Netherlands Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Switzerland Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Switzerland Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Poland Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Poland Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure South Asia Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure South Asia a Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure India Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure India Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Pakistan Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Pakistan Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Bangladesh Spinal Muscular Atrophy Medicine Consumption and Growth Rate

Forecast (2022-2027)

Figure Bangladesh Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Southeast Asia Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Southeast Asia Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Indonesia Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Indonesia Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Thailand Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Thailand Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Singapore Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Singapore Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Malaysia Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Malaysia Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Philippines Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Philippines Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Vietnam Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Vietnam Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Myanmar Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Myanmar Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Middle East Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Middle East Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Turkey Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Turkey Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Saudi Arabia Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Saudi Arabia Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Iran Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Iran Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure United Arab Emirates Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure United Arab Emirates Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Israel Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Israel Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Iraq Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Iraq Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Qatar Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Qatar Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Kuwait Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Kuwait Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Oman Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Oman Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Africa Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Africa Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast



(2022-2027)

Figure Nigeria Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Nigeria Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure South Africa Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure South Africa Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Egypt Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Egypt Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Algeria Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Algeria Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Morocco Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast (2022-2027)

Figure Morocco Spinal Muscular Atrophy Medicine Value and Growth Rate Forecast (2022-2027)

Figure Oceania Spinal Muscular Atrophy Medicine Consumption and Growth Rate Forecast

## I would like to order

Product name: 2021-2027 Global and Regional Spinal Muscular Atrophy Medicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report Standard Version

Product link: <https://marketpublishers.com/r/224406461AB8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/224406461AB8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970